{"id":4250,"date":"2015-05-05T07:49:37","date_gmt":"2015-05-05T07:49:37","guid":{"rendered":"https:\/\/jurmed.ro\/medici\/?p=4250"},"modified":"2015-05-05T07:49:37","modified_gmt":"2015-05-05T07:49:37","slug":"bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului","status":"publish","type":"post","link":"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/","title":{"rendered":"Bayer sus\u0163ine cercetarea european\u0103 \u00een domeniul biomarkerilor cancerului"},"content":{"rendered":"<p style=\"text-align: justify\"><a href=\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/05\/bayer.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft  wp-image-4251\" src=\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/05\/bayer-300x203.jpg\" alt=\"bayer\" width=\"301\" height=\"204\" srcset=\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/05\/bayer-300x203.jpg 300w, https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/05\/bayer.jpg 331w\" sizes=\"auto, (max-width: 301px) 100vw, 301px\" \/><\/a><\/p>\n<p style=\"text-align: justify\">Bayer HealthCare \u015fi Centrul Medical Universitar din\u00a0Hamburg-Eppendorf (UKE) sunt principalii coordonatori ai parteneriatului interna\u0163ional nou-\u00eencheiat CANCER-ID, pentru dezvoltarea \u015fi validarea tehnologiilor inovatoare de detectare a biomarkerilor din s\u00e2nge \u00een bolile canceroase. Proiectul de cinci ani se va axa pe stabilirea unor standarde comun acceptate pentru izolarea, identificarea \u015fi analiza biomarkerilor circulan\u0163i, \u00een scopul de a \u00eembun\u0103t\u0103\u0163i nivelul de dezvoltare a medicamentelor personalizate destinate pacien\u0163ilor bolnavi de cancer. CANCER-ID este un parteneriat public-privat, sus\u0163inut de Ini\u0163iativa european\u0103 privind medicamentele inovatoare (IMI).<\/p>\n<p style=\"text-align: justify\">Biomarkerii din s\u00e2nge, cum sunt celulele tumorale circulante (CTC), ADN-ul tumoral circulant (ADNtc) \u015fi micromoleculele de ARN (miRNAs), sunt poten\u0163iali indicatori ai \u00eenc\u0103rc\u0103turii tumorale la pacien\u0163ii care sufer\u0103 de cancer. Determinarea acestor markeri din s\u00e2nge poate oferi o metod\u0103 suplimentar\u0103 inestimabil\u0103 de terapie modern\u0103 a cancerului: pe l\u00e2ng\u0103 aceea c\u0103 sunt deosebit de importante \u00een situa\u0163iile \u00een care biopsiile tumorale nu sunt accesibile, testele pe baz\u0103 de s\u00e2nge pot permite o monitorizare continu\u0103 a markerilor bolii, asigur\u00e2nd o modalitate de a monitoriza \u00eendeaproape eficien\u0163a tratamentului \u015fi, eventual, de a ghida alegerea metodei de terapie.<\/p>\n<p style=\"text-align: justify\"><em>\u201cCANCER-ID reprezint\u0103 un excelent exemplu de proiect \u00een care un parteneriat public-privat permite o abordare de cercetare \u00een colaborare, pentru a veni cu concepte inovatoare \u00een terapia modern\u0103 a cancerului\u201d,<\/em> spune Dr. Thomas Schlange, Cercet\u0103tor Principal al programului de Cercetare Global\u0103 \u00een domeniul Biomarkerilor din cadrul departamentului Bayer HealthCare Global Drug Discovery \u015fi Coordonator al proiectului CANCER-ID. <em>\u201eParteneriatul reune\u015fte o echip\u0103 mare de speciali\u015fti cu experien\u0163\u0103 \u00een domeniul biomarkerilor, at\u00e2t din mediul academic, c\u00e2t \u015fi din industria de profil, precum \u015fi companii mai mici, cre\u00e2ndu-se astfel o re\u0163ea european\u0103 de competen\u0163e suplimentare, care dep\u0103\u015fe\u015fte cu mult orizontul colabor\u0103rilor tradi\u0163ionale de tip unu-la-unu dintre industrie \u015fi mediul academic.\u201d<\/em><\/p>\n<p style=\"text-align: justify\">Provoc\u0103rile importante \u00een dezvoltarea tuturor biomarkerilor circulan\u0163i sunt precizia, specificitatea \u015fi standardizarea analizei, precum \u015fi validarea acesteia. \u00cen ultima faz\u0103 a proiectului, analizele validate vor fi implementate \u00een teste clinice controlate, pentru a demonstra larga lor aplicabilitate \u015fi utilitatea clinic\u0103 \u00een tratarea pacien\u0163ilor care sufer\u0103 de cancer.<\/p>\n<p style=\"text-align: justify\">\u201c<em>Analiza pe baz\u0103 de s\u00e2nge a celulelor \u015fi acizilor nucleici deriva\u0163i din tumori ofer\u0103 un concept cu totul nou de \u201ebiopsii lichide\u201d, care permite recep\u0163ionarea \u00een timp real a unor informa\u0163ii relevante pentru diagnosticarea \u015fi tratamentul cancerului\u201d,<\/em> a spus Prof. Klaus Pantel, \u015eeful Departamentului de Biologie Tumoral\u0103 de la Centrul Medical Universitar din Hamburg-Eppendorf, Germania, \u015fi coordonatorul academic al parteneriatului CANCER-ID. \u201cProiectul CANCER-ID \u00eenchide pr\u0103pastia considerabil\u0103 dintre cercetarea fundamental\u0103 axat\u0103 pe metodele moi de detectare \u015fi caracterizare a celulelor tumorale circulante \u015fi a acizilor nucleici \u015fi dezvoltarea unor teste solide, validate, necesare pentru a introduce conceptul de \u201ebiopsie lichid\u0103\u201d \u00een cadrul clinicii.\u201d<\/p>\n<p style=\"text-align: justify\">Parteneriatul CANCER-ID cuprinde companii industriale din domeniul farmaceutic \u015fi din afara acestuia, universit\u0103\u0163i \u015fi institute de studii clinice, precum \u015fi \u00eentreprinderi mici \u015fi mijlocii (IMM-uri) de pe \u00eentreg teritoriul Europei. Cei 33 de parteneri din cadrul consor\u0163iului sunt to\u0163i factori-cheie \u00een domeniile lor de activitate, ei alc\u0103tuind o re\u0163ea unic\u0103 de exper\u0163i \u00een domenii precum biologia tumoral\u0103, dezvoltarea markerilor biologici, \u015ftiin\u0163ele clinice \u015fi bioinformatica. Contribu\u0163iile \u00een natur\u0103 din partea partenerilor industriali, \u00een valoare de cca. 8,2 milioane de euro, sunt completate de finan\u0163\u0103ri IMI din Cel de-al \u015eaptelea Program-Cadru al Uniunii Europene, rezult\u00e2nd un buget total de 14,5 milioane de euro.<\/p>\n<p style=\"text-align: justify\"><strong>Despre Ini\u0163iativa European\u0103 privind Medicamentele Inovatoare (IMI) <\/strong><\/p>\n<p style=\"text-align: justify\">Ini\u0163iativa privind Medicamentele Inovatoare (IMI) \u00ee\u015fi propune s\u0103 \u00eembun\u0103t\u0103\u0163easc\u0103 nivelul de s\u0103n\u0103tate prin accelerarea dezvolt\u0103rii unor medicamente inovatoare \u015fi gr\u0103birea accesului pacien\u0163ilor la ele, \u00een special \u00een zonele \u00een care exist\u0103 o necesitate medical\u0103 sau social\u0103 nesatisf\u0103cut\u0103. Reu\u015fe\u015fte acest lucru prin facilitatea colabor\u0103rii dintre factorii-cheie implica\u0163i \u00een cercet\u0103rile din domeniul \u00eengrijirii s\u0103n\u0103t\u0103\u0163ii, incluz\u00e2nd aici universit\u0103\u0163i, industria farmaceutic\u0103 \u015fi alte industrii conexe, \u00eentreprinderile mici \u015fi mijlocii (IMM-uri), organiza\u0163ii de pacien\u0163i \u015fi autorit\u0103\u0163i de reglementare din domeniul medicamentelor.<\/p>\n<p style=\"text-align: justify\">IMI este un parteneriat \u00eencheiat \u00eentre Uniunea European\u0103 \u015fi industria farmaceutic\u0103 din Europa, reprezentat\u0103 de Federa\u0163ia European\u0103 a Industriilor \u015fi Asocia\u0163iilor Farmaceutice (EFPIA). Prin intermediul Programului IMI 2, IMI dispune de un buget de 3,3 miliarde de euro pentru perioada 2014-2024. Jum\u0103tate din aceast\u0103 sum\u0103 provine din proiectul de cercetare \u015fi inova\u0163ie al Uniunii Europene, Horizon 2020.\u00a0 Cealalt\u0103 jum\u0103tate provine de la companiile mari, cu prec\u0103dere din domeniul farmaceutic. Acestea nu primesc finan\u0163\u0103ri de la Uniunea European\u0103, dar contribuie la proiecte \u201e\u00een natur\u0103\u201d \u2013 de pild\u0103, prin donarea de ore de lucru din programul cercet\u0103torilor lor sau prin asigurarea accesului la dot\u0103ri sau resurse de cercetare.<\/p>\n<p style=\"text-align: justify\">Cercet\u0103rile care au condus la aceste rezultate au primit sus\u0163inere din partea \u00centreprinderii Comune din cadrul Ini\u0163iativei privind Medicamentele Inovatoare, \u00een baza acordului de finan\u0163are nr. [115749], unele din aceste resurse fiind reprezentate de contribu\u0163ii financiare din partea Celui de-al \u015eaptelea Program-Cadru al Uniunii Europene (FP7\/2007-2013) \u015fi de contribu\u0163ii \u00een natur\u0103 din partea companiilor EFPIA.<\/p>\n<p style=\"text-align: justify\">Mai multe informa\u0163ii disponibile la: <a href=\"http:\/\/www.imi.europa.eu\/\">www.imi.europa.eu<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer HealthCare \u015fi Centrul Medical Universitar din\u00a0Hamburg-Eppendorf (UKE) sunt principalii coordonatori ai parteneriatului interna\u0163ional nou-\u00eencheiat CANCER-ID, pentru dezvoltarea \u015fi validarea tehnologiilor inovatoare de detectare a biomarkerilor din s\u00e2nge \u00een bolile [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[168],"tags":[225,226],"class_list":["post-4250","post","type-post","status-publish","format-standard","category-oncologie","tag-biomarker","tag-cancer-id"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bayer sus\u0163ine cercetarea european\u0103 \u00een domeniul biomarkerilor cancerului - Jurmed - Medici<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/\" \/>\n<meta property=\"og:locale\" content=\"ro_RO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer sus\u0163ine cercetarea european\u0103 \u00een domeniul biomarkerilor cancerului - Jurmed - Medici\" \/>\n<meta property=\"og:description\" content=\"Bayer HealthCare \u015fi Centrul Medical Universitar din\u00a0Hamburg-Eppendorf (UKE) sunt principalii coordonatori ai parteneriatului interna\u0163ional nou-\u00eencheiat CANCER-ID, pentru dezvoltarea \u015fi validarea tehnologiilor inovatoare de detectare a biomarkerilor din s\u00e2nge \u00een bolile [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/\" \/>\n<meta property=\"og:site_name\" content=\"Jurmed - Medici\" \/>\n<meta property=\"article:published_time\" content=\"2015-05-05T07:49:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/05\/bayer-300x203.jpg\" \/>\n<meta name=\"author\" content=\"ralucab\" \/>\n<meta name=\"twitter:label1\" content=\"Scris de\" \/>\n\t<meta name=\"twitter:data1\" content=\"ralucab\" \/>\n\t<meta name=\"twitter:label2\" content=\"Timp estimat pentru citire\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/\"},\"author\":{\"name\":\"ralucab\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/364b734872ee04688e0b7121c65eaa35\"},\"headline\":\"Bayer sus\u0163ine cercetarea european\u0103 \u00een domeniul biomarkerilor cancerului\",\"datePublished\":\"2015-05-05T07:49:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/\"},\"wordCount\":876,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/05\/bayer-300x203.jpg\",\"keywords\":[\"biomarker\",\"CANCER-ID\"],\"articleSection\":[\"Oncologie\"],\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/\",\"url\":\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/\",\"name\":\"Bayer sus\u0163ine cercetarea european\u0103 \u00een domeniul biomarkerilor cancerului - Jurmed - Medici\",\"isPartOf\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/05\/bayer-300x203.jpg\",\"datePublished\":\"2015-05-05T07:49:37+00:00\",\"author\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/364b734872ee04688e0b7121c65eaa35\"},\"breadcrumb\":{\"@id\":\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#breadcrumb\"},\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#primaryimage\",\"url\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/05\/bayer.jpg\",\"contentUrl\":\"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/05\/bayer.jpg\",\"width\":331,\"height\":224,\"caption\":\"Eylea\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/jurmed.ro\/medici\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bayer sus\u0163ine cercetarea european\u0103 \u00een domeniul biomarkerilor cancerului\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#website\",\"url\":\"https:\/\/jurmed.ro\/medici\/\",\"name\":\"Jurmed - Medici\",\"description\":\"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/jurmed.ro\/medici\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ro-RO\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/364b734872ee04688e0b7121c65eaa35\",\"name\":\"ralucab\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/247da7eca7bcc01a299ead1f5ff5ecede6d54a6373d3f9437c1c12da13a216c6?s=96&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/247da7eca7bcc01a299ead1f5ff5ecede6d54a6373d3f9437c1c12da13a216c6?s=96&r=g\",\"caption\":\"ralucab\"},\"url\":\"https:\/\/jurmed.ro\/medici\/author\/ralucabocancia\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bayer sus\u0163ine cercetarea european\u0103 \u00een domeniul biomarkerilor cancerului - Jurmed - Medici","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/","og_locale":"ro_RO","og_type":"article","og_title":"Bayer sus\u0163ine cercetarea european\u0103 \u00een domeniul biomarkerilor cancerului - Jurmed - Medici","og_description":"Bayer HealthCare \u015fi Centrul Medical Universitar din\u00a0Hamburg-Eppendorf (UKE) sunt principalii coordonatori ai parteneriatului interna\u0163ional nou-\u00eencheiat CANCER-ID, pentru dezvoltarea \u015fi validarea tehnologiilor inovatoare de detectare a biomarkerilor din s\u00e2nge \u00een bolile [&hellip;]","og_url":"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/","og_site_name":"Jurmed - Medici","article_published_time":"2015-05-05T07:49:37+00:00","og_image":[{"url":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/05\/bayer-300x203.jpg","type":"","width":"","height":""}],"author":"ralucab","twitter_misc":{"Scris de":"ralucab","Timp estimat pentru citire":"4 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#article","isPartOf":{"@id":"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/"},"author":{"name":"ralucab","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/364b734872ee04688e0b7121c65eaa35"},"headline":"Bayer sus\u0163ine cercetarea european\u0103 \u00een domeniul biomarkerilor cancerului","datePublished":"2015-05-05T07:49:37+00:00","mainEntityOfPage":{"@id":"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/"},"wordCount":876,"commentCount":0,"image":{"@id":"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/05\/bayer-300x203.jpg","keywords":["biomarker","CANCER-ID"],"articleSection":["Oncologie"],"inLanguage":"ro-RO","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/","url":"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/","name":"Bayer sus\u0163ine cercetarea european\u0103 \u00een domeniul biomarkerilor cancerului - Jurmed - Medici","isPartOf":{"@id":"https:\/\/jurmed.ro\/medici\/#website"},"primaryImageOfPage":{"@id":"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#primaryimage"},"image":{"@id":"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#primaryimage"},"thumbnailUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/05\/bayer-300x203.jpg","datePublished":"2015-05-05T07:49:37+00:00","author":{"@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/364b734872ee04688e0b7121c65eaa35"},"breadcrumb":{"@id":"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#breadcrumb"},"inLanguage":"ro-RO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/"]}]},{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#primaryimage","url":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/05\/bayer.jpg","contentUrl":"https:\/\/jurmed.ro\/medici\/wp-content\/uploads\/sites\/2\/2015\/05\/bayer.jpg","width":331,"height":224,"caption":"Eylea"},{"@type":"BreadcrumbList","@id":"https:\/\/jurmed.ro\/medici\/bayer-sustine-cercetarea-europeana-in-domeniul-biomarkerilor-cancerului\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/jurmed.ro\/medici\/"},{"@type":"ListItem","position":2,"name":"Bayer sus\u0163ine cercetarea european\u0103 \u00een domeniul biomarkerilor cancerului"}]},{"@type":"WebSite","@id":"https:\/\/jurmed.ro\/medici\/#website","url":"https:\/\/jurmed.ro\/medici\/","name":"Jurmed - Medici","description":"JURMED \u2013 Jurnal de Sanatate este o publicatie lunara de informare si preventie medicala. Revista si site-ul au un continut bogat de articole si informatii cu adresabilitate catre publicul larg.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/jurmed.ro\/medici\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ro-RO"},{"@type":"Person","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/364b734872ee04688e0b7121c65eaa35","name":"ralucab","image":{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/jurmed.ro\/medici\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/247da7eca7bcc01a299ead1f5ff5ecede6d54a6373d3f9437c1c12da13a216c6?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/247da7eca7bcc01a299ead1f5ff5ecede6d54a6373d3f9437c1c12da13a216c6?s=96&r=g","caption":"ralucab"},"url":"https:\/\/jurmed.ro\/medici\/author\/ralucabocancia\/"}]}},"_links":{"self":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/4250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/comments?post=4250"}],"version-history":[{"count":1,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/4250\/revisions"}],"predecessor-version":[{"id":4252,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/posts\/4250\/revisions\/4252"}],"wp:attachment":[{"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/media?parent=4250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/categories?post=4250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jurmed.ro\/medici\/wp-json\/wp\/v2\/tags?post=4250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}